▶Clindamycinincreases the effects ofsuxamethonium.r
Anecdotal
▶Corticosteroidsare predicted to decrease the effects of
suxamethonium.rAnecdotal
▶Suxamethoniumis predicted to increase the risk of
cardiovascular side-effects when given withdigoxin.r
Anecdotal
▶Irinotecanis predicted to increase the risk of prolonged
neuromuscular blockade when given withsuxamethonium.
oTheoretical
▶Intravenousmagnesiumis predicted to increase the effects of
suxamethonium.oStudy
▶Metoclopramideincreases the effects ofsuxamethonium.
oStudy
▶Penicillins(piperacillin)increase the effects ofsuxamethonium.
oStudy
▶SSRIspotentially increase the risk of prolonged
neuromuscular blockade when given withsuxamethonium.
qTheoretical
Sympathomimetics, inotropic
dobutamine.dopamine..
▶Sympathomimetics, inotropicare predicted to decrease the
effects ofapraclonidine. Avoid.rTheoretical
▶Beta blockers, non-selectiveincrease the risk of hypertension
and bradycardia when given withdobutamine.r
Theoretical
▶Beta blockers, selectiveincrease the risk of hypertension and
bradycardia when given withdobutamine.oTheoretical
▶Entacaponeis predicted to increase the risk of cardiovascular
side-effects when given withsympathomimetics, inotropic.
oTheoretical
▶Ergometrinepotentially increases the risk of peripheral
vasoconstriction when given withdopamine. Avoid.r
Anecdotal
▶Guanethidineis predicted to increase the effects ofdopamine.
rTheoretical
▶Sympathomimetics, inotropicare predicted to increase the risk
of elevated blood pressure when given withlinezolid. Avoid.
rTheoretical
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of a hypertensive crisis when
given withsympathomimetics, inotropic. Avoid and for 14 days
after stopping the MAOI.rTheoretical
▶Monoamine-oxidase B inhibitorsare predicted to increase the
risk of a hypertensive crisis when given with
sympathomimetics, inotropic. Avoid.rAnecdotal
▶Opicaponeis predicted to increase the risk of cardiovascular
side-effects when given withsympathomimetics, inotropic.
rTheoretical
▶Tolcaponeis predicted to increase the risk of cardiovascular
side-effects when given withsympathomimetics, inotropic.
oTheoretical
Sympathomimetics, vasoconstrictor
adrenaline/epinephrine.ephedrine.isometheptene.metaraminol
.midodrine.noradrenaline/norepinephrine.phenylephrine.
pseudoephedrine.xylometazoline..ROUTE-SPECIFIC INFORMATIONSince systemic absorption can
follow topical application, the possibility of interactions
should be borne in mind.▶Ephedrineincreases the risk of side-effects when given with
aminophylline. Avoid in children.oStudy
▶Sympathomimetics, vasoconstrictorare predicted to decrease
the effects ofapraclonidine. Avoid.rTheoretical
▶Atropineincreases the risk of severe hypertension when given
withphenylephrine.rStudy
▶Beta blockers, non-selectiveare predicted to increase the risk
of hypertension and bradycardia when given with
sympathomimetics, vasoconstrictor(adrenaline/epinephrine,
noradrenaline/norepinephrine).rStudy
▶Beta blockers, selectiveare predicted to increase the risk of
hypertension and bradycardia when given with
sympathomimetics, vasoconstrictor(adrenaline/epinephrine,
noradrenaline/norepinephrine).rStudy
▶Isometheptenepotentially increases the risk of side-effects
when given withdopamine receptor agonists(bromocriptine).
Avoid.rAnecdotal
▶Entacaponeis predicted to increase the risk of cardiovascular
side-effects when given withsympathomimetics, vasoconstrictor
(adrenaline/epinephrine, noradrenaline/norepinephrine).
oStudy
▶Ergometrineis predicted to increase the risk of peripheral
vasoconstriction when given with
noradrenaline/norepinephrine.rAnecdotal
▶Guanethidineincreases the effects ofmetaraminol.r
Anecdotal
▶Guanethidineincreases the effects ofphenylephrine.r
Study
▶Guanethidineis predicted to increase the effects of
sympathomimetics, vasoconstrictor(adrenaline/epinephrine,
noradrenaline/norepinephrine).oStudy
▶Pseudoephedrineincreases the risk of elevated blood pressure
when given withlinezolid. Avoid.rStudy
▶Sympathomimetics, vasoconstrictor(adrenaline/epinephrine,
ephedrine, isometheptene, noradrenaline/norepinephrine,
phenylephrine)are predicted to increase the risk of elevated
blood pressure when given withlinezolid. Avoid.r
Theoretical
▶Mianserindecreases the effects ofephedrine.rAnecdotal
▶Moclobemideis predicted to increase the risk of a hypertensive
crisis when given withsympathomimetics, vasoconstrictor
(ephedrine, isometheptene, phenylephrine, pseudoephedrine).
Avoid.rStudy
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the risk of a hypertensive crisis when
given withsympathomimetics, vasoconstrictor. Avoid and for
14 days after stopping the MAOI.rStudy
▶Monoamine-oxidase B inhibitorsare predicted to increase the
risk of a hypertensive crisis when given with
sympathomimetics, vasoconstrictor. Avoid.rAnecdotal
▶Opicaponeis predicted to increase the risk of cardiovascular
side-effects when given withsympathomimetics, vasoconstrictor
(adrenaline/epinephrine, noradrenaline/norepinephrine).
rTheoretical
▶Ephedrineincreases the risk of side-effects when given with
theophylline. Avoid in children.oStudy
▶Tolcaponeis predicted to increase the effects of
sympathomimetics, vasoconstrictor(adrenaline/epinephrine,
noradrenaline/norepinephrine).oTheoretical
▶Tricyclic antidepressantsare predicted to decrease the effects
ofephedrine. Avoid.rStudy
▶Tricyclic antidepressantsincrease the effects of
sympathomimetics, vasoconstrictor(adrenaline/epinephrine,
noradrenaline/norepinephrine, phenylephrine). Avoid.r
Study
Tacalcitol→see vitamin D substances
Tacrolimus→seeTABLE 2p. 847 (nephrotoxicity),TABLE 16p. 851
(increased serum potassium)
▶Pomelo might greatly increase the concentration of
tacrolimus.
▶Since systemic absorption can follow topical application,
the possibility of interactions should be borne in mind.
▶Alcohol (beverage)increases the risk of facialflushing and skin
irritation when given with topicaltacrolimus.oStudy
▶Antiarrhythmics(amiodarone)are predicted to increase the
concentration oftacrolimus.rAnecdotal
▶Antiarrhythmics(dronedarone)are predicted to increase the
concentration oftacrolimus.rStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)decrease the concentration of
tacrolimus. Monitor and adjust dose.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the concentration oftacrolimus.
rStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the concentration oftacrolimus. Monitor
and adjust dose.rStudyBNFC 2018 – 2019 Suxamethonium—Tacrolimus 997
Interactions|Appendix 1A1